

July 20, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,


We enclose herewith a copy of press release dated July 20, 2018 titled "Zydus receives final approval from the USFDA for Spironolactone Tablets USP."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Spironolactone Tablets USP

Ahmedabad, 20 July, 2018

Zydus Cadila has received the final approval from the USFDA to market Spironolactone Tablets USP (US RLD - Aldactone Tablets) in strengths of 25 mg, 50 mg and 100 mg. It is used to treat high blood pressure and heart failure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It is also used to treat swelling (edema) caused by certain conditions like heart failure and liver disease by removing excess fluid and improving symptoms such as breathing problems. The drug will be manufactured at the group's manufacturing facility at Baddi.

In line with this, the group now has 210 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
